magnus
Burlingame, US Β· Founded 2020 Β· 3 known investors
Magnus Medical develops SAINT, an FDA-cleared, accelerated form of TMS (transcranial magnetic stimulation) therapy that uses precision neuromodulation to treat Major Depressive Disorder, including treatment-resistant depression, over a 5-day course. The noninvasive, non-drug treatment was developed at Stanford's Brain Stimulation Lab and is delivered to patients through verified clinical providers.
Also known as Magnus Medical Β· Magnus Medical, Inc.
Founders & leadership
magnus was founded in 2020 by Nolan Williams.
Board
Investors Β· 3
Reported raises Β· per SEC filings
Form D private placements$89.3M disclosed across 2 rounds Β· 2025
βΆ$49MraisedMay 2026 Β· 10 investors Β· BiotechnologyRule 506(b)
- Heath LukatchDirector
- Andrew FirlikDirector
- Achal AchrolExecutive Officer, Director
- Brandon BentzleyExecutive Officer, Director
- Offering amount
- $77M
- Amount sold
- $49M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
βΆ$40.3MraisedMar 2025 Β· 10 investors Β· BiotechnologyRule 506(b)
- Christian GormsenExecutive Officer, Director
- Vikram LambaExecutive Officer
- Xingjuan ChaoDirector
- Nolan WilliamsDirector
- Andrew FirlikDirector
- Heath LukatchDirector
- Offering amount
- $59M
- Amount sold
- $40.3M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Magnus Medical, Inc. is a medical device company based in Burlingame, California that develops and commercializes SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), an accelerated, individually targeted form of transcranial magnetic stimulation for major depressive disorder, including treatment-resistant depression. The therapy is delivered over five days: patients are assessed by a Verified SAINT Provider, undergo an approximately 45-minute functional MRI scan that maps their brain's neural circuitry, receive a personalized stimulation target computed by the company's targeting algorithm, and then complete ten 10-minute stimulation sessions per day with 50-minute breaks between sessions.
The underlying SAINT technology was developed by psychiatrists and neuroscientists at Stanford University's Brain Stimulation Lab and licensed exclusively to Magnus Medical for commercialization. The FDA granted the technology Breakthrough Device Designation in 2021 and 510(k) clearance in September 2022 for the treatment of MDD in adults who have not achieved satisfactory improvement from prior antidepressant medications in the current episode. The company positions the treatment against conventional TMS, which it describes as requiring 6-9 weeks and 30-36 clinic visits.
Beyond depression in adults, the company is pursuing additional indications, including a Department of Defense-funded multisite pivotal study of SAINT for postpartum depression, with the first patient enrolled at the University of Massachusetts. Magnus also engages with reimbursement policy, announcing CMS payment rates for SAINT under the Hospital Outpatient Prospective Payment System for 2025 and 2026, and has asserted its exclusive rights to Stanford-assigned accelerated neuromodulation patents by sending cease-and-desist letters to companies it believes infringe them.
Founding story
Magnus Medical was co-founded by Brett Wingeier, Ph.D. (CEO) and Brandon Bentzley, M.D., Ph.D. (CSO) to commercialize SAINT technology developed at Stanford University's Brain Stimulation Lab, which was licensed exclusively to the company. At launch the senior team also included Scott Ashworth and Romain Moreau-Gobard.
Business model
Magnus Medical commercializes the Magnus/SAINT neuromodulation system through clinical providers and health systems, which deliver the therapy to patients as Verified SAINT Providers. Reimbursement in the U.S. hospital outpatient setting is supported by CMS payment rates established under the Outpatient Prospective Payment System rules for 2025 and 2026.
Traction
Published trials reported that 79% of participants in the active arm of a double-blind randomized controlled trial entered remission versus 13% in the sham arm, and 19 of 21 participants (90%) entered remission in an earlier pilot trial. Commercially, the company reports expanding access as health systems scale nationwide adoption, secured CMS outpatient payment rates for 2025 and continued payment stability for 2026, and enrolled the first patient in an $11.6M Department of Defense-supported pivotal postpartum depression study at the University of Massachusetts.
Latest developments
Recent company announcements cover expanded access to the five-day SAINT therapy as health systems scale nationwide adoption, cease-and-desist letters to companies believed to infringe its exclusively licensed accelerated neuromodulation patents, the first patient enrolled at the University of Massachusetts in an $11.6M Department of Defense-supported pivotal multisite study of SAINT for postpartum depression, and a December 2, 2025 announcement of uninterrupted 2026 payment stability for SAINT under the CMS OPPS final rule.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company describes SAINT as the first and only FDA-cleared therapy to achieve remission from major depressive disorder in five days, and positions itself as a pioneer in precision neuromodulation for brain health conditions. Its differentiation is framed relative to standard TMS protocols requiring 6-9 weeks and 30-36 clinic visits.
Differentiation rests on treatment duration and personalization: a five-day course with 10 sessions per day versus 6-9 weeks of standard TMS, fMRI-derived individualized targeting, FDA Breakthrough Device Designation and 510(k) clearance, published randomized controlled trial and pilot data in the American Journal of Psychiatry, and an exclusive patent license from Stanford University that the company actively enforces.
Technology
SAINT combines functional MRI-based imaging of an individual patient's brain connectivity with a proprietary targeting algorithm that selects a personalized stimulation site, plus accelerated intermittent theta-burst-style stimulation patterns delivered in a condensed multi-session daily schedule. The approach is noninvasive and non-drug. The company holds an exclusive license to issued U.S. patents assigned to Stanford University covering accelerated neuromodulation.
Go-to-market
The company markets to two audiences through its website β people seeking treatment and healthcare professionals β and operates a provider-finder directing patients to Verified SAINT Providers. Adoption is scaled through leading health systems, and clinician advocates such as directors of TMS clinics feature in the company's testimonials. A newsroom and press kit support media outreach, and consumer media coverage (including CNN reporting and podcasts) has featured the therapy.
Adults with major depressive disorder, particularly treatment-resistant depression that has not improved sufficiently with antidepressant medication or other treatments; clinically, the buyers are psychiatric clinics, TMS practices and hospital/health-system outpatient programs. A pivotal study is also evaluating the therapy in postpartum depression.
Geography
Headquartered at 1350 Old Bayshore Highway, Suite 600, Burlingame, California 94010, USA, with therapy delivered through a network of Verified SAINT Providers and health systems in the United States.
History
The company emerged publicly in October 2021, announcing FDA Breakthrough Device Designation for its individualized rapid-acting neurostimulation technology alongside $25 million in Series A financing co-led by JAZZ Venture Partners and Red Tree Venture Capital, timed with publication of the SAINT randomized controlled trial in the American Journal of Psychiatry. The FDA granted 510(k) clearance for the SAINT Neuromodulation System in September 2022 for adults with major depressive disorder. Subsequent milestones include CMS payment rates for hospital outpatient use in 2025 and 2026, a DoD-funded pivotal postpartum depression study, and patent-enforcement actions protecting its exclusive Stanford license.
Risks & controversies
The company has sent cease-and-desist letters to companies it believes infringe the accelerated neuromodulation patents it exclusively licenses from Stanford University, indicating active intellectual property disputes in a rapidly evolving mental health treatment market. Its U.S. commercial economics depend in part on CMS hospital outpatient payment rates, which are set annually.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 8
launches, deals, and filingsMagnus Medical announced uninterrupted 2026 payment stability for SAINT neuromodulation in the CMS Hospital Outpatient Prospective Payment System final rule.
An $11.6M Department of Defense-supported pivotal multisite study evaluating SAINT as a rapid, personalized, drug-free neuromodulation therapy for postpartum depression enrolled its first patient at the University of Massachusetts.
$11.6M source β
As exclusive licensee of accelerated neuromodulation patents assigned to Stanford University, Magnus Medical sent cease-and-desist letters to companies it believes infringe its patents.
The SAINT Neuromodulation System received 510(k) clearance from the FDA for treatment of major depressive disorder in adults who failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.
$25M source β
The FDA granted Magnus Medical Breakthrough Device Designation for its individualized, rapid-acting, noninvasive neurostimulation technology for major depressive disorder in patients who had not improved sufficiently with antidepressant medication or other treatments.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- magnusmagnusmed.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does magnus do?
- Magnus Medical makes SAINT, an FDA-cleared five-day accelerated TMS neuromodulation therapy for major depressive disorder.
- Who founded magnus?
- magnus was founded by Nolan Williams in 2020.
- Who are magnus's investors?
- magnus's investors include JAZZ Venture Partners, Dolby Family Ventures, Red Tree Venture.
- How much funding has magnus raised?
- magnus has disclosed $89.3M raised across 2 rounds.
- Where is magnus headquartered?
- magnus is headquartered in Burlingame, US.